Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27253970 | 0.80 | ELANE (0.43) | CYP2A6CHRNB2CHRNA4PTGS2CYP2C19 | |
| SCHEMBL27446446 | 0.76 | KDM4C (0.36) | CYP2A6 | |
| SCHEMBL27250761 | 0.76 | CYP3A4 (0.36) | CYP2A6 | |
| SCHEMBL20377738 | 0.76 | POLB (0.59) | CYP11B2POLBCHRNB4CHRNA3IDO1 | |
| SCHEMBL27446399 | 0.72 | CYP3A4 (0.32) | — | |
| SCHEMBL18011080 | 0.72 | MAPT (0.48) | CYP11B2POLBPTGS2MAPT | |
| SCHEMBL8814485 | 0.71 | CYP11B2 (0.45) | CYP11B2POLBCHRNB4CHRNA3IDO1 | |
| SCHEMBL27913463 | 0.71 | NAPRT (0.46) | CYP11B2POLBCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL9827675 | 0.71 | ALDH1A1 (0.46) | MAPTRAB9ACYP2C19 | |
| SCHEMBL31366255 | 0.70 | POLB (0.61) | CYP11B2POLBCYP2A6IDO1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-03-24 | — | — | US | disclosed |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-02-17 | — | — | US | disclosed |
| CN-119112897-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119119022-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-119119023-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-4470609-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2024-12-04 | — | — | EP | disclosed |
| CN-119060040-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-3911648-B1 | 6'-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)-2-PYRIMIDINYL]AMINO]CYCLOPENTYL]AMINO][1(2H),3'-BIPYRIDIN]-2-ONE AS PCSK9 INHIBITOR AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-10-23 | — | — | EP | disclosed |
| CN-113574055-B | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-113574055-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2021-10-29 | — | — | CN | disclosed |
| CN-113412258-A | PCSK9 inhibitors and methods of use thereof | 阿斯利康(瑞典)有限公司 | 2021-09-17 | — | — | CN | disclosed |
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-09-17 | — | — | US | disclosed |
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-09-17 | — | — | US | disclosed |
| WO-2020150474-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200231584-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-07-23 | — | — | US | disclosed |
| WO-2020150473-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150473-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200231584-A1 | PCSK9 Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2020-07-23 | — | — | US | disclosed |
| WO-2020150474-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | DOGMA THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291041-A1 | PCSK9 Inhibitors and Methods of Use Thereof | PCSK9, PCSK7, PCSK6 | CYP11B2 1109/4885POLB 4345/4885CYP2A6 3094/4885 |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | CYP11B2 869/4885POLB 4247/4885CYP2A6 864/4885 |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, LDLR, PCSK7 | CYP11B2 1576/4885POLB 4151/4885CYP2A6 1415/4885 |
| US-20200231584-A1 | PCSK9 Inhibitors and Methods of Use Thereof | PCSK9, PCSK7, PCSK6 | CYP11B2 819/4885POLB 4170/4885CYP2A6 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.